Re-analysis of Selzentry trial confirms efficacy in treatment-naïve HIV patients
This article was originally published in Scrip
Pfizerhas announced the positive outcome from a re-analysis of a head-to-head Phase III trial pitching its first-in-class CCR5 antagonist, Selzentry (maraviroc) against a standard of care, efavirenz, showing non-inferiority in treatment-naïve patients, with fewer side effects. The findings were presented at the annual meeting of infectious diseases society of America (IDSA) and ICAAC in Washington DC.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.